• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

STAAR Surgical marks sale of 3 million Implantable Collamer Lenses


The company’s EVO family of Implantable Collamer Lenses for myopia, astigmatism and presbyopia, are designed to correct vision through a minimally invasive procedure.

(Image Credit: AdobeStock)

(Image Credit: AdobeStock)

STAAR Surgical Co. announced that more than 3 million ICLs have been sold globally.

According to a news release,1 the company’s EVO family of Implantable Collamer Lenses (EVO ICL) for myopia, astigmatism and presbyopia, are designed to correct vision through a minimally invasive procedure.

Moreover, the company noted the EVO ICL lens is implanted between the iris and the natural crystalline lens in a quick and safe 20 to 30 minute procedure. It’s biocompatible and does not remove corneal tissue, so it works with the natural eye, and the lens implant is removable by a surgeon, if desired.

Myopia is the most common refractive visual error and is a global epidemic that is expected to impact over half the world’s population by 2050.2

“We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction as we celebrate our three million lens milestone,” Tom Frinzi, president and CEO of STAAR Surgical, said in the new release. “EVO ICL is the next logical step in refractive innovation with clear differentiators in patient outcomes and satisfaction. Our lens-based technology is ushering in the next generation of vision correction by helping to free patients from the struggle of daily contacts and eyeglasses.”

In October 2023, the company marked the 30th anniversary of its proprietary Implantable Collamer Lens.

EVO ICLs, which evolved from early-generation ICLs, offer a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for vision correction.

Most patients report improved vision immediately after the procedure, and 99.4% of patients would have the procedure again.3

1. STAAR Surgical Celebrates Three Million Implantable Collamer Lenses. www.businesswire.com. Published March 18, 2024. Accessed March 19, 2024. https://www.businesswire.com/news/home/20240318771746/en
2. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-42. doi: 10.1016/j.ophtha.2016.01.006. Epub 2016 Feb 11. PMID: 26875007.
3. STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer Lens (ICL). Press Release. Released October 17, 2023. Accessed March 19, 2024. https://investors.staar.com/press-releases/press-release-details/2023/STAAR-Surgical-Celebrates-30th-Anniversary-of-Implantable-Collamer-Lens-ICL/default.aspx
Related Videos
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.